Switch theme
Sign up to access all valuation multiples
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
1996
99
LTM Revenue $2.9B
LTM EBITDA $2.7B
$21.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Royalty Pharma has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $2.7B.
In the most recent fiscal year, Royalty Pharma achieved revenue of $2.3B and an EBITDA of $1.6B.
Royalty Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Royalty Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $2.7B | XXX | $1.6B | XXX | XXX | XXX |
| EBITDA Margin | 93% | XXX | 69% | XXX | XXX | XXX |
| EBIT | $2.7B | XXX | $1.3B | XXX | XXX | XXX |
| EBIT Margin | 93% | XXX | 57% | XXX | XXX | XXX |
| Net Profit | $2.5B | XXX | $859M | XXX | XXX | XXX |
| Net Margin | 87% | XXX | 38% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Royalty Pharma's stock price is $36.
Royalty Pharma has current market cap of $15.2B, and EV of $21.0B.
See Royalty Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21.0B | $15.2B | XXX | XXX | XXX | XXX | $4.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Royalty Pharma has market cap of $15.2B and EV of $21.0B.
Royalty Pharma's trades at 9.3x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Royalty Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Royalty Pharma has a P/E ratio of 6.0x.
See valuation multiples for Royalty Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.2B | XXX | $15.2B | XXX | XXX | XXX |
| EV (current) | $21.0B | XXX | $21.0B | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 7.8x | XXX | 16.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.0x | XXX | 17.7x | XXX | XXX | XXX |
| EV/FCF | 7.5x | XXX | 7.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRoyalty Pharma's last 12 month revenue growth is 6%
Royalty Pharma's revenue per employee in the last FY averaged $22.9M, while opex per employee averaged $9.8M for the same period.
Royalty Pharma's rule of 40 is 86% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Royalty Pharma's rule of X is 108% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Royalty Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 93% | XXX | 69% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | 86% | XXX | 75% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $22.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $9.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Royalty Pharma acquired XXX companies to date.
Last acquisition by Royalty Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Royalty Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Royalty Pharma founded? | Royalty Pharma was founded in 1996. |
| Where is Royalty Pharma headquartered? | Royalty Pharma is headquartered in United States of America. |
| How many employees does Royalty Pharma have? | As of today, Royalty Pharma has 99 employees. |
| Who is the CEO of Royalty Pharma? | Royalty Pharma's CEO is Mr. Pablo Legorreta. |
| Is Royalty Pharma publicy listed? | Yes, Royalty Pharma is a public company listed on NAS. |
| What is the stock symbol of Royalty Pharma? | Royalty Pharma trades under RPRX ticker. |
| When did Royalty Pharma go public? | Royalty Pharma went public in 2020. |
| Who are competitors of Royalty Pharma? | Similar companies to Royalty Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Royalty Pharma? | Royalty Pharma's current market cap is $15.2B |
| What is the current revenue of Royalty Pharma? | Royalty Pharma's last 12 months revenue is $2.9B. |
| What is the current revenue growth of Royalty Pharma? | Royalty Pharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Royalty Pharma? | Current revenue multiple of Royalty Pharma is 7.3x. |
| Is Royalty Pharma profitable? | Yes, Royalty Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Royalty Pharma? | Royalty Pharma's last 12 months EBITDA is $2.7B. |
| What is Royalty Pharma's EBITDA margin? | Royalty Pharma's last 12 months EBITDA margin is 93%. |
| What is the current EV/EBITDA multiple of Royalty Pharma? | Current EBITDA multiple of Royalty Pharma is 7.8x. |
| What is the current FCF of Royalty Pharma? | Royalty Pharma's last 12 months FCF is $2.8B. |
| What is Royalty Pharma's FCF margin? | Royalty Pharma's last 12 months FCF margin is 97%. |
| What is the current EV/FCF multiple of Royalty Pharma? | Current FCF multiple of Royalty Pharma is 7.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
